Prognostic significance of thymidylate synthase in patients with metastatic colorectal cancer who receive protracted venous infusions of 5-fluorouracil

被引：14

作者：

Hosokawa A. ^{[1
]}

Yamada Y. ^{[1
]}

Shimada Y. ^{[1
]}

Muro K. ^{[1
]}

Hamaguchi T. ^{[1
]}

Morita H. ^{[1
]}

Araake M. ^{[1
]}

Orita H. ^{[1
]}

Shirao K. ^{[1
]}

机构：

[1] Gastrointestinal Oncology Division, National Cancer Center Hospital, Chuo-ku, Tokyo 104-0045

来源：

International Journal of Clinical Oncology | 2004年 / 9卷 / 5期

关键词：

Colorectal cancer; Continuous infusion; Fluorouracil; Prognostic factor; Thymidylate synthase;

D O I：

10.1007/s10147-004-0425-1

中图分类号：

学科分类号：

摘要：

Background. This study was conducted to evaluate the prognostic significance of thymidylate synthase (TS) expression in the tumor tissue of patients with metastatic colorectal cancer (CRC) who received protracted venous infusions of 5-fluorouracil (5-FU). Methods. We retrospectively analyzed the prognostic value of TS expression as compared with other clinical prognostic factors in 57 patients with metastatic CRC. Results. On univariate analysis, survival was significantly related to TS expression (low vs high; P = 0.0015), alkaline phosphatase (ALP) level (<300 vs ≥300 IU/l; P = 0.0037), performance status (0 or 1 vs 2 or 3; P = 0.0073), and white blood cell count (<10 000/mm3 vs ≥10 000/mm3; P = 0.0001), with number of metastatic sites (1 vs ≥2; P = 0.06) approaching significance. On multivariate analysis, survival was significantly related to TS expression (hazard ratio [HR], 2.97) and ALP level (HR, 2.26). Conclusion. In patients with metastatic CRC who received protracted venous infusions of 5-FU, TS expression was related to survival independently of other established clinical prognostic factors.

引用

页码：388 / 392

页数：4

共 18 条

[11]

Assersohn L., Norman A., Cunningham D., Et al., Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma, Br J Cancer, 79, pp. 1800-1805, (1999)

[12]

Edler L., Heim M.E., Qiuntero C., Et al., Prognostic factors of advanced colorectal cancer patients, Eur J Cancer Clin Oncol, 22, pp. 1231-1237, (1986)

[13]

Graf W., Glimelius B., Pahlman L., Et al., Determinants of prognosis in advanced colorectal cancer, Eur J Cancer, 27, pp. 1119-1123, (1991)

[14]

Massacesi C., Pistilli B., Valeri M., Et al., Predictors of short-term survival and progression to chemotherapy in patients with advanced colorectal cancer treated with 5-fluorouracil-based regimens, Am J Clin Oncol, 25, pp. 140-148, (2002)

[15]

Steinberg J., Erlichman C., Gadalla T., Et al., Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid, Eur J Cancer, 28 A, pp. 1817-1820, (1992)

[16]

Chang A.E., Steinberg S.M., Culnane M., Et al., Determinants of survival in patients with unresectable colorectal liver metastases, J Surg Oncol, 40, pp. 245-251, (1989)

[17]

Webb A., Scott-Mackie P., Cunningham D., Et al., The prognostic value of CEA, beta HCG, AFP, CA125, CA19-9, C-erb B-2, and beta HCG immunohistochemistry in advanced colorectal cancer, Ann Oncol, 6, pp. 581-587, (1995)

[18]

Gonen M., Hummer A., Zervoudakis A., Et al., Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer, J Clin Oncol, 21, pp. 406-412, (2003)

← 1 2 →